AstraZeneca, Xenogen oncology deal

AstraZeneca (AZN; LSE:AZN) will use in vivo imaging technology from Xenogen (Alameda, Calif.) in its oncology research programs. Under the three year licensing deal, Xenogen's technology will be used ...